In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Radiance Medical Systems Inc.

Division of Endologix Inc.
www.radiance.net

Latest From Radiance Medical Systems Inc.

Bio-Star Fund Taps Clinical Stars

Medical practice changes so rapidly these days that many say if device companies don't have a presence in the operating room every single day, they'll rapidly fall behind the technological curve. The same is true for VCs evaluating the market potential of new technologies, which is why many partners at successful venture firms are physicians. Now, a new VC--Bio-Star Private Equity Fund, founded and funded by practicing physicians-is going a step further.
Medical Device Business Strategies

Endologix' Marriage of Convenience

Endologix needed cash, Radiance Medical needed a new market. Each found what it needed in a merger which will give Endologix the resources to develop its AAA graft line while helping Radiance segue out of a coronary brachytherapy market all but decimated by drug-eluting stents.
Business Strategies

Hijacking the Restenosis Market

Innovative device companies have always had to contend with the Sword of Damocles of unexpected technological obsolescence, but for would-be developers of interventional devices for the prevention of restenosis, the sword is dangling perilously close. In the RAVEL trial, a 238-patient clinical trial on a drug eluting stent, treated patients experienced 0% restenosis compared to 26% in the control group. Now, device developers with alternatives to stents reposition themselves to sustain businesses in the face of potentially shrinking target markets. Many argue that they will serve certain applications better than stents; others hope to work with drug-coated stents to enhance performance, many believe that economics will leave room for alternative approaches, and still others are getting out of the coronary business entirely.
Medical Device Business Strategies

The Unstable State of Plaque Detection

Recent research points to unstable, rather than stenotic plaque, as a major cause of heart attacks. Cardiologists, as much as entrepreneurs and large companies, are therefore driving the creation of new cardiac detection platforms based on characterizing arterial plaque in order to identify patients that are unaware that they are at risk of suffering a myocardial infarction. First-generation detection tools are well along in development, but the scientific understanding about plaque is evolving so rapidly, technologies may be obsolete by the time they are ready for commercialization. Finally, looking for heart attack risk in symptomless patients means screening apparently healthy patients based on risk factors. Clinicians aren't yet prepared for the treatment implications and payers aren't ready for the economic burden of widespread screening, and this presents one of the greatest challenges for companies introducing new plaque detection technologies.
Medical Device Strategy
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • CardioVascular Dynamics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Endologix Inc.
  • Senior Management
  • Jeffrey Thiel, CEO
    Stephen R Kroll, VP, Admin., Fin. & CFO
    Tom Brown, VP, Market Dev.
    Edward F Smith, PhD, VP, R&D
  • Contact Info
  • Radiance Medical Systems Inc.
    Phone: (949) 457-9546
    13700 Alton Pkwy.
    Ste. 160
    Irvine, CA 92618
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register